Amgen wins OK on psoriasis drug
From Times Wire Services
Amgen Inc. won an advisory panel’s support for the use of its drug Enbrel in children with moderate to severe psoriasis.
The outside experts voted, 8 to 5, to recommend that the Food and Drug Administration expand Enbrel’s approved uses to children with the sometime debilitating skin disorder, after testimony weighing the drug’s benefits against its potential for cancer and other side effects. The FDA isn’t required to follow the panel’s lead, though it usually does.
